These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 15618944)
1. Development of subtype selective GABAA modulators. Dawson GR; Collinson N; Atack JR CNS Spectr; 2005 Jan; 10(1):21-7. PubMed ID: 15618944 [TBL] [Abstract][Full Text] [Related]
2. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. Rowlett JK; Cook JM; Duke AN; Platt DM CNS Spectr; 2005 Jan; 10(1):40-8. PubMed ID: 15618946 [TBL] [Abstract][Full Text] [Related]
3. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. Ator NA CNS Spectr; 2005 Jan; 10(1):31-9. PubMed ID: 15618945 [TBL] [Abstract][Full Text] [Related]
4. To what extent is it possible to dissociate the anxiolytic and sedative/hypnotic properties of GABAA receptors modulators? Chagraoui A; Skiba M; Thuillez C; Thibaut F Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():189-202. PubMed ID: 27495357 [TBL] [Abstract][Full Text] [Related]
5. The GABAA-BZR complex as target for the development of anxiolytic drugs. Trincavelli ML; Da Pozzo E; Daniele S; Martini C Curr Top Med Chem; 2012; 12(4):254-69. PubMed ID: 22204488 [TBL] [Abstract][Full Text] [Related]
6. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test. Mathiasen LS; Rodgers RJ; Mirza NR Behav Pharmacol; 2007 May; 18(3):191-203. PubMed ID: 17426483 [TBL] [Abstract][Full Text] [Related]
7. Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Smith TA Br J Biomed Sci; 2001; 58(2):111-21. PubMed ID: 11440203 [TBL] [Abstract][Full Text] [Related]
8. Benzodiazepine-GABAA receptor complex ligands in two models of anxiety. Nazar M; Jessa M; Płaźnik A J Neural Transm (Vienna); 1997; 104(6-7):733-46. PubMed ID: 9444572 [TBL] [Abstract][Full Text] [Related]
9. [GABA(A) benzodiazepine receptors and epilepsy]. Sieghart W Wien Klin Wochenschr; 1990 Mar; 102(7):197-201. PubMed ID: 2160756 [TBL] [Abstract][Full Text] [Related]
10. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Atack JR Expert Opin Investig Drugs; 2005 May; 14(5):601-18. PubMed ID: 15926867 [TBL] [Abstract][Full Text] [Related]
11. Subtype selectivity of α+β- site ligands of GABAA receptors: identification of the first highly specific positive modulators at α6β2/3γ2 receptors. Varagic Z; Ramerstorfer J; Huang S; Rallapalli S; Sarto-Jackson I; Cook J; Sieghart W; Ernst M Br J Pharmacol; 2013 May; 169(2):384-99. PubMed ID: 23472935 [TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Sieghart W Adv Pharmacol; 2015; 72():53-96. PubMed ID: 25600367 [TBL] [Abstract][Full Text] [Related]
13. Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Savić MM; Huang S; Furtmüller R; Clayton T; Huck S; Obradović DI; Ugresić ND; Sieghart W; Bokonjić DR; Cook JM Neuropsychopharmacology; 2008 Jan; 33(2):332-9. PubMed ID: 17392731 [TBL] [Abstract][Full Text] [Related]
19. GABA A/Bz receptor subtypes as targets for selective drugs. Da Settimo F; Taliani S; Trincavelli ML; Montali M; Martini C Curr Med Chem; 2007; 14(25):2680-701. PubMed ID: 17979718 [TBL] [Abstract][Full Text] [Related]
20. Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. Licata SC; Platt DM; Cook JM; Sarma PV; Griebel G; Rowlett JK J Pharmacol Exp Ther; 2005 Jun; 313(3):1118-25. PubMed ID: 15687371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]